Biomea Fusion (BMEA) News Today $3.97 -0.09 (-2.22%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Biomea Fusion’s Strategic Focus on Metabolic Diseases and Promising Pipeline Advances Garner Buy RatingJanuary 14, 2025 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for Biomea Fusion (NASDAQ:BMEA)HC Wainwright reiterated a "buy" rating and issued a $40.00 price target on shares of Biomea Fusion in a research note on Tuesday.January 14, 2025 | marketbeat.comAnalysts Set Biomea Fusion, Inc. (NASDAQ:BMEA) Target Price at $39.36January 14, 2025 | americanbankingnews.comBiomea Fusion to become diabetes, obesity medicines companyJanuary 13, 2025 | markets.businessinsider.comBiomea Fusion price target lowered to $16 from $128 at D. Boral CapitalJanuary 13, 2025 | markets.businessinsider.comBiomea Fusion to Become a Diabetes & Obesity Medicines CompanyJanuary 13, 2025 | markets.businessinsider.comBiomea Fusion, Inc. (NASDAQ:BMEA) Receives Average Rating of "Buy" from AnalystsShares of Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) have received a consensus rating of "Buy" from the thirteen brokerages that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, nine have issued a buy recommendation and twJanuary 11, 2025 | marketbeat.comBiomea Fusion's (BMEA) Buy Rating Reaffirmed at D. Boral CapitalD. Boral Capital reiterated a "buy" rating and set a $128.00 price target on shares of Biomea Fusion in a report on Friday.January 10, 2025 | marketbeat.comScotiabank Sticks to Its Buy Rating for Biomea Fusion (BMEA)January 8, 2025 | markets.businessinsider.comBiomea Fusion reports new preclinical data on icovamenib-semaglutide studyJanuary 8, 2025 | markets.businessinsider.comBiomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination StudyJanuary 7, 2025 | markets.businessinsider.comBiomea Fusion, Inc. (NASDAQ:BMEA) Sees Large Growth in Short InterestBiomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 10,870,000 shares, an increase of 9.6% from the November 30th total of 9,920,000 shares. Based on an average daily trading volume, of 953,600 shares, the short-interest ratio is currently 11.4 days. Currently, 34.4% of the company's shares are sold short.December 31, 2024 | marketbeat.comBarclays Remains a Hold on Biomea Fusion (BMEA)December 18, 2024 | markets.businessinsider.comBiomea Fusion (BMEA) Receives a Buy from Truist FinancialDecember 18, 2024 | markets.businessinsider.comBiomea Fusion, Inc.: Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 DiabetesDecember 18, 2024 | finanznachrichten.deWhat's Driving Biomea Fusion? Stock Soars 25%December 17, 2024 | markets.businessinsider.comBiomea Fusion's (BMEA) Buy Rating Reiterated at D. Boral CapitalD. Boral Capital restated a "buy" rating and set a $128.00 price objective on shares of Biomea Fusion in a research report on Tuesday.December 17, 2024 | marketbeat.comBiomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 DiabetesDecember 17, 2024 | globenewswire.comBiomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Rating of "Buy" by AnalystsBiomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has earned a consensus recommendation of "Buy" from the thirteen research firms that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and twoDecember 17, 2024 | marketbeat.comBiomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)December 16, 2024 | globenewswire.comBiomea Fusion's (BMEA) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $40.00 price target on shares of Biomea Fusion in a research note on Monday.December 16, 2024 | marketbeat.comBiomea Fusion, Inc. (NASDAQ:BMEA) Short Interest Up 5.4% in NovemberBiomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) was the recipient of a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 9,920,000 shares, a growth of 5.4% from the November 15th total of 9,410,000 shares. Based on an average daily trading volume, of 773,600 shares, the short-interest ratio is currently 12.8 days. Currently, 31.4% of the company's stock are sold short.December 16, 2024 | marketbeat.comD. Boral maintains Buy rating, $128 target on Biomea Fusion after presentationsDecember 14, 2024 | markets.businessinsider.comBiomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)December 12, 2024 | globenewswire.comOppenheimer Keeps Their Buy Rating on Biomea Fusion (BMEA)December 11, 2024 | markets.businessinsider.comBiomea Fusion (BMEA) Gets a Hold from BarclaysDecember 11, 2024 | markets.businessinsider.comBiomea Fusion (NASDAQ:BMEA) Earns "Buy" Rating from D. Boral CapitalD. Boral Capital restated a "buy" rating and set a $128.00 price objective on shares of Biomea Fusion in a report on Tuesday.December 10, 2024 | marketbeat.comBiomea Fusion announces preliminary COVALENT-103 study dataDecember 10, 2024 | markets.businessinsider.comBiomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute LeukemiaDecember 9, 2024 | globenewswire.comBiomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute LeukemiaDecember 6, 2024 | globenewswire.comBiomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)December 2, 2024 | globenewswire.comScotiabank Sticks to Their Buy Rating for Biomea Fusion (BMEA)November 26, 2024 | markets.businessinsider.comBiomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) have earned an average rating of "Buy" from the twelve analysts that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two havNovember 22, 2024 | marketbeat.comPositive Buy Recommendation for Biomea Fusion Amid Promising Diabetes Treatment Developments in COVALENT-111 Phase 2 TrialNovember 22, 2024 | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for Biomea Fusion (NASDAQ:BMEA)HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of Biomea Fusion in a research note on Thursday.November 21, 2024 | marketbeat.comBiomea Fusion’s icovamenib shows efficacy in Type 2 diabetes trialNovember 19, 2024 | markets.businessinsider.comWe're A Little Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn RateNovember 13, 2024 | finance.yahoo.comBiomea Fusion FY2024 EPS Estimate Raised by HC WainwrightBiomea Fusion, Inc. (NASDAQ:BMEA - Free Report) - Equities researchers at HC Wainwright raised their FY2024 earnings per share estimates for Biomea Fusion in a report issued on Thursday, October 31st. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($3.97November 4, 2024 | marketbeat.comBiomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)November 1, 2024 | globenewswire.comTruist Financial Remains a Buy on Biomea Fusion (BMEA)October 31, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Biomea Fusion (BMEA)October 31, 2024 | markets.businessinsider.comBiomea Fusion, Inc.: Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate HighlightsOctober 31, 2024 | finanznachrichten.deBiomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist CandidateOctober 30, 2024 | globenewswire.comBarclays Keeps Their Hold Rating on Biomea Fusion (BMEA)October 30, 2024 | markets.businessinsider.comBiomea Fusion price target raised to $11 from $9 at BarclaysOctober 30, 2024 | markets.businessinsider.comBarclays Increases Biomea Fusion (NASDAQ:BMEA) Price Target to $11.00Barclays lifted their price target on shares of Biomea Fusion from $9.00 to $11.00 and gave the company an "equal weight" rating in a research note on Wednesday.October 30, 2024 | marketbeat.comBiomea Fusion (NASDAQ:BMEA) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPSBiomea Fusion (NASDAQ:BMEA - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.91) earnings per share for the quarter, beating analysts' consensus estimates of ($0.94) by $0.03.October 30, 2024 | marketbeat.comBiomea Fusion Reports Q3 2024 Financial ResultsOctober 30, 2024 | msn.comBiomea Fusion Reports Third Quarter 2024 Financial Results and Corporate HighlightsOctober 29, 2024 | globenewswire.comBiomea Fusion options imply 6.1% move in share price post-earningsOctober 29, 2024 | markets.businessinsider.com Get Biomea Fusion News Delivered to You Automatically Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter. Email Address BMEA Media Mentions By Week BMEA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BMEA News Sentiment▼0.140.50▲Average Medical News Sentiment BMEA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BMEA Articles This Week▼73▲BMEA Articles Average Week Get Biomea Fusion News Delivered to You Automatically Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VECT News KURA News TECX News CRGX News HUMA News ANNX News PHVS News KROS News MREO News RAPP News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BMEA) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomea Fusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BMEA Stock Alerts